07 Aug 2013, BioSpectrum Bureau , BioSpectrum
New Delhi: The facilities of the Indian generics major Ranbaxy have come under the scanner of the country's health ministry only months after the company paid a $500 million settlement to the US for non-adherence to Good Manufacturing Practices (GMP).
After this incident, the Drugs Controller General of India (DCGI) had been ordered to review the facilities of Ranbaxy in India. "This was done to ascertain the quality of drugs manufactured for the domestic market," said health minister Mr Ghulam Nabi Azad.
He added, "As per US law, a drug is considered adulterated if it is not manufactured, processed and packed in conformity with the Current Good Manufacturing Practice (cGMP) regulations of the US FDA."